Summary Inflection Biosciences Ltd (Inflection Biosciences) is a drug development company focused on discovery and development of small molecule therapeutics for the treatment of cancer.The company’s pipeline products include dual mechanism kinase inhibitors and pim kinase inhibitors including IBL-301, IBL-202 and IBL-100.
Inflection Biosciences product candidates are developed to target cancer pathways in various types of cancers such as ovarian, multiple myeloma, haematological malignancies, sold tumors including pancreatic, blood, breast, colorectal and oesophageal cancers.The company also focuses on mechanisms underlying aspects of cancer cell biology such as cell proliferation, DNA repair and metastasis.
It has operations with offices in Ireland and the UK. Inflection Biosciences is headquartered in Dublin, Ireland.
Inflection Biosciences Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
172 pages •
By Global Industry Analysts
• Apr 2021
- Global Myeloproliferative Disorders Drugs Market to Reach $9.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Myeloproliferative Disorders Drugs estimated at US$7.8 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at aCAGR of 3.4% over...
The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period (2020 - 2025). Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy and the growing number of patients with cardiac and cancer ailments. Targeted anticancer...
Fallopian Tube Cancer Market Report Overview Fallopian Tube Cancer market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Fallopian Tube Cancer market types and applications. It is a focused study on Fallopian Tube Cancer market space including...
“XmAb14045 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Blastic Plasmacytoid Dendritic Cell Neoplasm in 7 Major Markets. A detailed picture of the XmAb14045 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom),...
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 184.108.40.206) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 220.127.116.11) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes...
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 18.104.22.168) - Drugs in Development, 2021 Summary Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 22.214.171.124) - Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor...
573 pages •
By Global Industry Analysts
• Apr 2021
- Looking Beyond Today’s Challenges to Tomorrow’s Healthcare Needs. Genetic Testing to Reach $18.9 Billion as the Burden of Non-Communicable Diseases Grows Bigger
- The global market for Genetic Testing is forecast to reach US$18.9 billion by the year 2027, trailing a post COVID-19 CAGR of 8.6% over the...
Melanoma - Epidemiology Forecast to 2029
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the cancer clinical decision tools market are McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthineers, Elsevier B.V., Macmillan and National Decision Support Company. The global cancer clinical decision tools market is expected to decline from $0.38 billion in 2019 to $0.35...
Patient Data Management
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.